Your browser doesn't support javascript.
loading
Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker.
Taylor, Martin S; Wu, Connie; Fridy, Peter C; Zhang, Stephanie J; Senussi, Yasmeen; Wolters, Justina C; Cajuso, Tatiana; Cheng, Wen-Chih; Heaps, John D; Miller, Bryant D; Mori, Kei; Cohen, Limor; Jiang, Hua; Molloy, Kelly R; Chait, Brian T; Goggins, Michael G; Bhan, Irun; Franses, Joseph W; Yang, Xiaoyu; Taplin, Mary-Ellen; Wang, Xinan; Christiani, David C; Johnson, Bruce E; Meyerson, Matthew; Uppaluri, Ravindra; Egloff, Ann Marie; Denault, Elyssa N; Spring, Laura M; Wang, Tian-Li; Shih, Ie-Ming; Fairman, Jennifer E; Jung, Euihye; Arora, Kshitij S; Yilmaz, Osman H; Cohen, Sonia; Sharova, Tatyana; Chi, Gary; Norden, Bryanna L; Song, Yuhui; Nieman, Linda T; Pappas, Leontios; Parikh, Aparna R; Strickland, Matthew R; Corcoran, Ryan B; Mustelin, Tomas; Eng, George; Yilmaz, Ömer H; Matulonis, Ursula A; Chan, Andrew T; Skates, Steven J.
Afiliação
  • Taylor MS; Department of Pathology, Mass General Brigham and Harvard Medical School, Boston, Massachusetts.
  • Wu C; Department of Pathology, Mass General Brigham and Harvard Medical School, Boston, Massachusetts.
  • Fridy PC; Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts.
  • Zhang SJ; Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, New York.
  • Senussi Y; Department of Pathology, Mass General Brigham and Harvard Medical School, Boston, Massachusetts.
  • Wolters JC; Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts.
  • Cajuso T; Department of Pathology, Mass General Brigham and Harvard Medical School, Boston, Massachusetts.
  • Cheng WC; Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts.
  • Heaps JD; Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Miller BD; Department of Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Mori K; Department of Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Cohen L; Department of Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Jiang H; Department of Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Molloy KR; Department of Pathology, Mass General Brigham and Harvard Medical School, Boston, Massachusetts.
  • Chait BT; Healthcare Optics Research Laboratory, Canon U.S.A., Inc., Cambridge, Massachusetts.
  • Goggins MG; Department of Pathology, Mass General Brigham and Harvard Medical School, Boston, Massachusetts.
  • Bhan I; Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts.
  • Franses JW; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts.
  • Yang X; Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, New York.
  • Taplin ME; Laboratory of Mass Spectrometry and Gaseous Ion Chemistry, The Rockefeller University, New York, New York.
  • Wang X; Laboratory of Mass Spectrometry and Gaseous Ion Chemistry, The Rockefeller University, New York, New York.
  • Christiani DC; Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Johnson BE; Mass General Cancer Center and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Meyerson M; Mass General Cancer Center and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Uppaluri R; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Egloff AM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Denault EN; Department of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts.
  • Spring LM; Mass General Cancer Center and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Wang TL; Department of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts.
  • Shih IM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Fairman JE; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Jung E; Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Arora KS; Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Yilmaz OH; Mass General Cancer Center and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Cohen S; Mass General Cancer Center and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Sharova T; Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Chi G; Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Norden BL; Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Song Y; University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
  • Nieman LT; Department of Pathology, Mass General Brigham and Harvard Medical School, Boston, Massachusetts.
  • Pappas L; Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
  • Parikh AR; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Strickland MR; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Corcoran RB; Mass General Cancer Center and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Mustelin T; Mass General Cancer Center and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Eng G; Mass General Cancer Center and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Yilmaz ÖH; Mass General Cancer Center and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Matulonis UA; Mass General Cancer Center and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Chan AT; Mass General Cancer Center and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Skates SJ; Mass General Cancer Center and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Cancer Discov ; 13(12): 2532-2547, 2023 12 12.
Article em En | MEDLINE | ID: mdl-37698949
Improved biomarkers are needed for early cancer detection, risk stratification, treatment selection, and monitoring treatment response. Although proteins can be useful blood-based biomarkers, many have limited sensitivity or specificity for these applications. Long INterspersed Element-1 (LINE-1) open reading frame 1 protein (ORF1p) is a transposable element protein overexpressed in carcinomas and high-risk precursors during carcinogenesis with negligible expression in normal tissues, suggesting ORF1p could be a highly specific cancer biomarker. To explore ORF1p as a blood-based biomarker, we engineered ultrasensitive digital immunoassays that detect mid-attomolar (10-17 mol/L) ORF1p concentrations in plasma across multiple cancers with high specificity. Plasma ORF1p shows promise for early detection of ovarian cancer, improves diagnostic performance in a multianalyte panel, provides early therapeutic response monitoring in gastroesophageal cancers, and is prognostic for overall survival in gastroesophageal and colorectal cancers. Together, these observations nominate ORF1p as a multicancer biomarker with potential utility for disease detection and monitoring. SIGNIFICANCE: The LINE-1 ORF1p transposon protein is pervasively expressed in many cancers and is a highly specific biomarker of multiple common, lethal carcinomas and their high-risk precursors in tissue and blood. Ultrasensitive ORF1p assays from as little as 25 µL plasma are novel, rapid, cost-effective tools in cancer detection and monitoring. See related commentary by Doucet and Cristofari, p. 2502. This article is featured in Selected Articles from This Issue, p. 2489.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Carcinoma Tipo de estudo: Diagnostic_studies / Screening_studies Limite: Female / Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Carcinoma Tipo de estudo: Diagnostic_studies / Screening_studies Limite: Female / Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2023 Tipo de documento: Article